Keywords: Merck & Co, Victrelis, Pfizer, Macugen, Hepatitis C, Diabetic macular degeneration, Europe, EMA

Merck & Co gets EU approval for Victrelis; Pfizer withdraws Macugen indication extension

Article | 20 July 2011

Print This

US drug giant Merck & Co (NYSE: MRK) says that the European Commission has approved Victrelis (boceprevir) for the treatment ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in